Matrix Metalloproteinase-9 (279R/Q) Polymorphism is Associated with Clinical Severity and Airflow Limitation in Tunisian Patients with Chronic Obstructive Pulmonary Disease

Overview

Journal Mol Diagn Ther

Specialties Molecular Biology
Pathology
Pharmacology

Date 2015 Aug 26

PMID 26303146

Citations 4

Authors

Sarra Bchir

Hela Ben Nasr

Imen Rekik Hakim

Amel Ben Anes

Saloua Yacoub

Abdelhamid Garrouch

Mohamed Benzarti

Brigitte Bauvois

Zouhair Tabka

Karim Chahed

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to investigate the role of matrix metalloproteinase-9 (MMP-9) C-1562T and 279R/Q (836G>A) polymorphisms in the development of chronic obstructive pulmonary disease (COPD) in Tunisians and to determine their impact on disease progression and airflow obstruction.

Methods: Pulmonary functional tests were evaluated by body plethysmography. MMP-9 genotypes were determined in patients with COPD (n = 138) and healthy controls (n = 216) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Serum MMP-9 and interleukin-6 (IL-6) levels were determined by enzyme-linked immunosorbent assays (ELISA) and activity of MMP-9 was evaluated by gelatin zymography.

Results: No significant association was found between genetic variations in MMP-9 C-1562T and 279R/Q polymorphisms and the risk of development of COPD. However, a significant correlation was retrieved between the 279 R/Q polymorphism and disease severity (P = 0.02). In addition, homozygous Q (A) genotype was associated with a poorer lung function with a fall in forced expiratory volume in 1 s (FEV1) (%) and forced vital capacity (FVC%) among COPD patients compared with both AG and GG individuals (52.06 ± 19.6 vs. 59.08 ± 17.19, P = 0.03 and 72.41 ± 21.42 vs. 82.98 ± 16.48, P = 0.002, respectively). Using ELISA, a higher level of MMP-9 was found in patients with the CT genotype (P = 0.03), while no significant impact of the 279R/Q polymorphism was observed (P = 0.48). In contrast, by using zymography gel analysis, MMP-9 activity was enhanced in individuals carrying the R(G) allele in comparison with those homozygous for the Q(A) variant (P = 0.02).

Conclusion: Our results support a role for the 279R/Q polymorphism in physiological alterations that may affect progression and severity of COPD. These findings could be related to the decreased activity of MMP-9 among COPD patients carrying the 279Q variant.

Citing Articles

Association of the and gene polymorphisms with COPD risk: a meta-analysis.

Zhao H, Jiang X, Huang Q, Chen M, Xie Z Arch Med Sci. 2024; 20(1):196-206.

PMID: 38414455 PMC: 10895971. DOI: 10.5114/aoms/114117.

Genetic polymorphism of matrix metalloproteinase 9 and susceptibility to chronic obstructive pulmonary disease: A meta-analysis.

Yang X, Yu Y, Wang Y, Jiang W, Jiang W, Yin B J Med Biochem. 2022; 41(3):263-274.

PMID: 36042908 PMC: 9375530. DOI: 10.5937/jomb0-34155.

Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function.

Gilowska I, Kasper L, Bogacz K, Szczegielniak J, Szymasek T, Kasper M Biomed Res Int. 2019; 2018:6417415.

PMID: 30643813 PMC: 6311264. DOI: 10.1155/2018/6417415.

Concomitant elevations of MMP-9, NGAL, proMMP-9/NGAL and neutrophil elastase in serum of smokers with chronic obstructive pulmonary disease.

Bchir S, Ben Nasr H, Bouchet S, Benzarti M, Garrouch A, Tabka Z J Cell Mol Med. 2016; 21(7):1280-1291.

PMID: 28004483 PMC: 5487915. DOI: 10.1111/jcmm.13057.

References

Kumar M, Phougat N, Ruhil S, Dhankhar S, Balhara M, Chhillar A . Genomics of Chronic Obstructive Pulmonary Disease (COPD); Exploring the SNPs of Protease-Antiprotease Pathway. Curr Genomics. 2013; 14(3):204-13. PMC: 3664470. DOI: 10.2174/1389202911314030006. View

Schirmer H, Basso da Silva L, Teixeira P, Moreira J, Moreira A, Simon D . Matrix metalloproteinase gene polymorphisms: lack of association with chronic obstructive pulmonary disease in a Brazilian population. Genet Mol Res. 2009; 8(3):1028-34. DOI: 10.4238/vol8-3gmr596. View

Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S . Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999; 105(5):418-23. DOI: 10.1007/s004390051124. View

Zhang B, Ye S, Herrmann S, Eriksson P, de Maat M, Evans A . Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999; 99(14):1788-94. DOI: 10.1161/01.cir.99.14.1788. View

Albaiceta G, Gutierrez-Fernandez A, Parra D, Astudillo A, Garcia-Prieto E, Taboada F . Lack of matrix metalloproteinase-9 worsens ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2008; 294(3):L535-43. DOI: 10.1152/ajplung.00334.2007. View

Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M, Tabuena R . Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax. 2005; 60(4):277-81. PMC: 1747359. DOI: 10.1136/thx.2004.028936. View

Minematsu N, Nakamura H, Tateno H, Nakajima T, Yamaguchi K . Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun. 2001; 289(1):116-9. DOI: 10.1006/bbrc.2001.5936. View

Lee S, Kim M, Kang H, Yoo S, Choi Y, Lee W . Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration. 2010; 80(2):133-8. DOI: 10.1159/000284926. View

Montaner J, Fernandez-Cadenas I, Molina C, Monasterio J, Arenillas J, Ribo M . Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke. 2003; 34(12):2851-5. DOI: 10.1161/01.STR.0000098648.54429.1C. View

10.

Skarmoutsou E, DAmico F, Marchini M, Stivala F, Malaponte G, Scorza R . Analysis of matrix metalloproteinase-9 gene polymorphism -1562 C/T in patients suffering from systemic sclerosis with and without ulcers. Int J Mol Med. 2011; 27(6):873-7. DOI: 10.3892/ijmm.2011.661. View

11.

Ahluwalia T, Khullar M, Ahuja M, Kohli H, Bhansali A, Mohan V . Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One. 2009; 4(4):e5168. PMC: 2663813. DOI: 10.1371/journal.pone.0005168. View

12.

Parks W, Wilson C, Lopez-Boado Y . Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004; 4(8):617-29. DOI: 10.1038/nri1418. View

13.

Perotin J, Adam D, Vella-Boucaud J, Delepine G, Sandu S, Jonvel A . Delay of airway epithelial wound repair in COPD is associated with airflow obstruction severity. Respir Res. 2014; 15:151. PMC: 4251925. DOI: 10.1186/s12931-014-0151-9. View

14.

Pires D, Ascher D, Blundell T . mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics. 2013; 30(3):335-42. PMC: 3904523. DOI: 10.1093/bioinformatics/btt691. View

15.

Lose F, Thompson P, Duffy D, Stewart G, Kedda M . A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women. Thorax. 2005; 60(8):623-8. PMC: 1747496. DOI: 10.1136/thx.2004.026930. View

16.

Brajer B, Batura-Gabryel H, Nowicka A, Kuznar-Kaminska B, Szczepanik A . Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol. 2009; 59 Suppl 6:145-52. View

17.

Medley T, Cole T, Dart A, Gatzka C, Kingwell B . Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol. 2004; 24(8):1479-84. DOI: 10.1161/01.ATV.0000135656.49158.95. View

18.

Joos L, He J, Shepherdson M, Connett J, Anthonisen N, Pare P . The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet. 2002; 11(5):569-76. DOI: 10.1093/hmg/11.5.569. View

19.

Goldberg G, Strongin A, Collier I, Genrich L, Marmer B . Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 1992; 267(7):4583-91. View

20.

Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M . Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med. 2005; 172(11):1378-82. DOI: 10.1164/rccm.200506-953OC. View